학술논문
Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?
Document Type
Article
Author
Source
Subject
*LINEZOLID
*MULTIDRUG resistance
*TUBERCULOSIS treatment
*
*
Language
ISSN
2328-8957
Abstract
Linezolid (LNZ), a group 5 antituberculous drug (unclear efficacy), was used in the starter regimens of 23 adults with multidrug-resistant tuberculosis. The LNZ-containing regimens were effective in achieving culture conversions and relapse-free outcomes. The most frequent LNZ-related side effect was neuropathy. We propose that LNZ should be reclassified among bactericidal second-line drugs. [ABSTRACT FROM AUTHOR]